Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Saurabh J Bhave"'
Autor:
Manthan Kathrotiya, Vivek S Radhakrishnan, Saurabh J Bhave, Jeevan Kumar, Mita Roychowdhury, Indu Arun, Jayanta Das, Mammen Chandy, Reena Nair
Publikováno v:
Clinical Case Reports, Vol 9, Iss 2, Pp 873-877 (2021)
Abstract This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV‐negative relapsed PBL can be treated successfully and consolidated with an allogeneic haploi
Externí odkaz:
https://doaj.org/article/c05d3484a6d4478a9049bf4f1901ed3b
Autor:
Vinay Anand Guntiboina, Vivek S. Radhakrishnan, Jeevan Kumar, Saurabh J. Bhave, Sushant Vinarkar, Jayanta Das, Indu Arun, Deepak Kumar Mishra, Mammen Chandy, Reena Nair
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:780-784
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caab86bec09326e7cf540031c72feed7
https://doi.org/10.1016/j.clml.2022.05.005
https://doi.org/10.1016/j.clml.2022.05.005
Autor:
Bhagat S. Lali, Debdeep Dey, Saurabh J. Bhave, Mayur Parihar, Dayanand Lingegowda, Jayanta Das, Suvadip Chatterjee
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 42:501-505
Large B-cell lymphomas include both the commonly encountered, as well as not so frequent entities. We report a rare case of hepatic intravascular large B-cell lymphoma (IVLBCL). These cases usually pose a major challenge to timely diagnosis due to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f27fe89b2324a4d86e2546101c0b6de
https://doi.org/10.1055/s-0041-1735518
https://doi.org/10.1055/s-0041-1735518
Autor:
Vivek S. Radhakrishnan, Rajat Bajaj, Vasundhara Raina, Jeevan Kumar, Saurabh J. Bhave, Reghu K. Sukumaran Nair, Arijit Nag, Indu Arun, Lateef Zameer, Debdeep Dey, Neeraj Arora, Mayur Parihar, Jayanta Das, Rimpa B. Achari, Deepak K. Mishra, Mammen Chandy, Reena Nair
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2022)
Frontiers in Oncology, Vol 11 (2022)
IntroductionDespite high cure rates with standard treatment, 30% patients with Hodgkin lymphoma develop relapsed or refractory (R/R) disease. Salvage therapy followed by autologous hematopoietic cell transplantation (HCT) is considered standard of ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de2607953fcfdc1d2482ee52856aff7
https://doi.org/10.3389/fonc.2021.796270
https://doi.org/10.3389/fonc.2021.796270
Autor:
Vivek S Radhakrishnan, Naveed Tamboli, Shreya Das, Jeevan Kumar Garg, Arijit Nag, Saurabh J Bhave, Mayur Parihar, Sushant Vinarkar, Sumit Mukhopadhyay, Subhosmito Chakraborty, Deepak K Mishra, Reena Nair, Mammen Chandy
Publikováno v:
Blood. 138:2752-2752
Introduction: Pomalidomide is a third-generation immunomodulatory drug approved for relapsed and/or refractory Multiple Myeloma (RRMM). In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone demonstrated superior efficacy in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a13b8a466515ec30375673422d585925
https://doi.org/10.1182/blood-2021-151718
https://doi.org/10.1182/blood-2021-151718